DF
Duquesne Family Office is the personal investment firm of Stanley F. Druckenmiller, founded in 2010 after he closed his hedge fund Duquesne Capital. It manages the Druckenmiller family's wealth using a concentrated, macro-driven investment approach across public equities, venture investments, commodities, and credit opportunities.
35% of their portfolio is in Healthcare. Deal activity decreased year-over-year (2 deals in the last 12 months vs 5 prior). Average disclosed round size is $111.3M (across 21 rounds with reported amounts).
Portfolio
16
Fund Size
—
Top Stage
Series C
Last 12 Mo
2
Team
SM
Sue Meng
Partner and Managing Director
CC
Chance Cooley
Analyst
BB
Blake Balda
Investor
DB
Dan Berardo
Investor
DD
Daniel Du
Investor
EP
Emily Park
Investor
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
23 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Precision | Series D | $250M | Sep 2026 |
 Epicrispr Biotechnologies | Series C | $90M | Aug 2026 |
 MyOme, Inc. | Unknown | — | Dec 2025 |
 Q.ANT | Series A | — | Jul 2025 |
 Ledgebrook | Series C | $65M | Jun 2025 |
 Curative | Series B | $150M | Jan 2025 |
| Q.ANT | Series A | $80M | Jan 2025 |
 Purecycle | Unknown | $300M | Jan 2025 |
| Precision | Series C | $102M | Dec 2024 |
 MetOx | Series B | $15M | Nov 2024 |
 MetOx International, Inc. | Series B | $15M | Nov 2024 |
 Cellares | Series C | $255M | Aug 2023 |
| RRatio Therapeutics Inc. | Series A | $20M | Feb 2023 |
| RRatio Therapeutics Inc. | Seed | $20M | Jun 2022 |
 C2i Genomics | Series C | $100M | Apr 2021 |
| C2i Genomics | Series B | $100M | Apr 2021 |
| C2i Genomics | Seed | $100M | Jan 2021 |
 PROCEPT BioRobotics | Series G | $85M | Jan 2018 |
 SonoThera | Series B | $125M | — |
 Lean Technologies | Series B | $67.5M | — |
 Ratio | Series C | $70M | — |
| RRatio Therapeutics Inc. | Series C | $70M | — |
| Cellares | Series D | $257M | — |
Top Co-Investors
Bristol Myers Squibb4 shared
Eli Lilly and Company3 shared
Casdin Capital3 shared
Gobi Partners3 shared
NFX3 shared
Catalio Capital Management3 shared
Illumina Ventures2 shared
Perceptive Advisors2 shared
B Capital2 shared
S322 shared
LionBird2 shared
GG12 shared
DFJ Growth2 shared
EDBI2 shared
Gates Frontier2 shared
Baillie Gifford2 shared
Intuitive Ventures2 shared
Eclipse2 shared
Last updated: 7 October 2026